Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Biotechnology
The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important.   1 January 2012
Biotechnology
The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes.   1 January 2012
Biotechnology
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs.   1 January 2012
Americas
Practitioners can take heart from recent developments in the Brazilian courts, say Otto Licks and Anderson Nascimento.   1 May 2011
Biotechnology
A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains.   1 May 2011
Big Pharma
Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled.   1 May 2011
Americas
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007.   1 May 2011
Americas
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs.   1 May 2011
Americas
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes.   1 May 2011
Americas
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications.   1 May 2011